This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (28)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Morie A. Gertz, MD; Robert A. Kyle, MD

Arch Intern Med. 1990;150(3):629-633.

Abstract
• We followed up 153 patients with biopsy-proven primary systemic amyloidosis to determine their risk for acute nonlymphocytic leukemia or a dysmyelopoietic syndrome. In 10 patients cytogenetic abnormalities developed consistent with alkylatorinduced damage to hematopoietic cells. In this group, the total melphalan dose ranged from 476 to 2450 mg (median, 1764 mg) administered over 21 to 92 months (median, 38 months). Eight of the 10 patients died as a direct result of pancytopenia, 1 died of progressive renal amyloid, and 1 remains alive with persistent complex cytogenetic abnormalities. Four patients had acute nonlymphocytic leukemia; 5 had a dysmyelopoietic syndrome; and 1 had a nondiagnostic bone marrow examination. Although only 6.5% of the entire group had leukemia or a dysmyelopoietic syndrome, the actuarial risk in patients surviving 3.5 years was 21%. Median survival from onset of dysmyelopoietic syndrome or acute leukemia was 8.1 months.

(Arch Intern Med. 1990;150:629-633)

Author Affiliations
From the Dysproteinemia Clinic, Mayo Clinic and Mayo Foundation, Rochester, Minn.

Footnotes
Accepted for publication October 31,1989.

Reprint requests to Dysproteinemia Clinic, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (Dr Gertz).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

How I treat amyloidosis
Comenzo
Blood 2009;114:3147-3157.
ABSTRACT | FULL TEXT  

Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis
Gertz et al.
haematol 2008;93:1402-1406.
ABSTRACT | FULL TEXT  

Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628
Dhodapkar et al.
Blood 2004;104:3520-3526.
ABSTRACT | FULL TEXT  

Prevalence-Value-Accuracy Plots: A New Method for Comparing Diagnostic Tests Based on Misclassification Costs
Remaley et al.
Clin. Chem. 1999;45:934-941.
ABSTRACT | FULL TEXT